Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.34 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4485285 | 0.79 | CYP1A2 (0.49) | SNCACYSLTR2CYSLTR1HIF1APDE10A | |
| Bromide SCHEMBL7086028 | 0.79 | NR4A2 (0.40) | SNCAPDE10ACYP1A2 | |
| Hydrochloric Acid SCHEMBL2401263 | 0.76 | CYP1A2 (0.49) | CYSLTR2CYSLTR1HIF1APDE10ACYP1A2 | |
| Hydrochloric Acid SCHEMBL8071622 | 0.74 | CYP1A2 (0.47) | CYSLTR2CYSLTR1PDE10ACYP1A2 | |
| Bromide SCHEMBL8128341 | 0.70 | PPARA (0.33) | SNCAHIF1APDE10AAPP | |
| SCHEMBL4061337 | 0.70 | CCR1 (0.48) | CYSLTR2CYSLTR1PDE10AAPPTERT | |
| SCHEMBL6089466 | 0.70 | TERT (0.37) | CYSLTR2CYSLTR1PDE10AAPPTERT | |
| Hydrochloric Acid SCHEMBL7512828 | 0.69 | ALDH1A1 (0.41) | CYSLTR2CYSLTR1HIF1APDE10AAPP | |
| Bromide SCHEMBL19994660 | 0.68 | SNCA (0.44) | SNCAHIF1ACYP1A2 | |
| Bromide SCHEMBL9086038 | 0.68 | SNCA (0.38) | SNCAHIF1AAPPCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | disclosed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0699188-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1996-03-06 | — | — | EP | disclosed |
| US-5438141-A | Antiasthmatic agents, antiallergens | MERCK FROSST CANADA, INC. (CA) | 1995-08-01 | — | — | US | disclosed |
| WO-1994027968-A1 | QUINOLINE DERIVATIVES AS LEUKOTRIENE ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | SNCA 4671/4885CYSLTR2 1/4885CYSLTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.